Experimental Alzheimer's Drug That Fights a Tough-to-Target Protein Shows Promise at Slowing Cognitive Decline in a Clinical Trial
Reported by Smithsonian Magazine ·
Smithsonian Magazine reports: "Experimental Alzheimer's Drug That Fights a Tough-to-Target Protein Shows Promise at Slowing Cognitive Decline in a Clinical Trial". It explores practical choices and cultural shifts in sustainable living. Read the full story at Smithsonian Magazine for complete details.
Read the full story at Smithsonian Magazine ↗P x BC News curates sustainability journalism. The reporting above belongs to Smithsonian Magazine; the summary is our own. We always link to the original.
Related coverage
- Development
The brain-body connection is key to reducing the risk of cognitive decline and Alzheimer’s disease
Caribbean News Global
- Lifestyle
This Newly Approved Narcolepsy Drug Is the First to Target the Sleep Disorder's Root Cause Rather Than Its Symptoms
Smithsonian Magazine
- Innovation
Cratering oil use in China shows the death spiral that could end oil
Electrek
- World
Chilling footage shows Molly Ticehurst’s murderer saying ‘I can’t believe I just did that’, court hears
The Guardian